Enzolytics Inc
OTC:ENZC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Enzolytics Inc
Common Stock
Enzolytics Inc
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Enzolytics Inc
OTC:ENZC
|
Common Stock
$100
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Common Stock
$18m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Common Stock
$1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Common Stock
$2.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Common Stock
$101.8k
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
Enzolytics Inc
Glance View
Enzolytics, Inc. is a biotechnology company, which engages in the development and commercialization of drugs for infectious disease treatments. The company is headquartered in Plano, Texas. The company went IPO on 2008-12-29. The firm is engaged in the commercialization of its proteins for the treatment of debilitating infectious diseases. The firm is focused in developing monoclonal antibody therapy and treating infectious diseases. The company has anti-HIV therapeutics and a methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The firm has clinically tested anti-HIV therapeutics. The firm has developed a cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus. The firm has also created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus, and diphtheria. The firm is testing these antibodies to prepare them for use as therapies against these diseases.
See Also
What is Enzolytics Inc's Common Stock?
Common Stock
100
USD
Based on the financial report for Dec 31, 2012, Enzolytics Inc's Common Stock amounts to 100 USD.
What is Enzolytics Inc's Common Stock growth rate?
Common Stock CAGR 3Y
-21%
The average annual Common Stock growth rates for Enzolytics Inc have been -21% over the past three years .
